UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer

Science translational medicine, 2019-09, Vol.11 (510)

2019

Volltextzugriff (PDF)

Tipifarnib as a Precision Therapy for HRAS -Mutant Head and Neck Squamous Cell Carcinomas

Molecular cancer therapeutics, 2020-09, Vol.19 (9), p.1784-1796

2020

Volltextzugriff (PDF)

Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor

Nature medicine, 2010-02, Vol.16 (2), p.205-213

2010

Volltextzugriff (PDF)

Targeting of the MNK–eIF4E axis in blast crisis chronic myeloid leukemia inhibits leukemia stem cell function

Proceedings of the National Academy of Sciences - PNAS, 2013-06, Vol.110 (25), p.E2298-E2307

2013

Volltextzugriff (PDF)

Resistance to mTOR kinase inhibitors in lymphoma cells lacking 4EBP1

PloS one, 2014-02, Vol.9 (2), p.e88865-e88865

2014

Volltextzugriff (PDF)

Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor

Cell, 2018-01, Vol.172 (3), p.578-589.e17

2018

Volltextzugriff (PDF)

Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State

Cancer discovery, 2016-03, Vol.6 (3), p.316-329

2016

Volltextzugriff (PDF)

KRAS G12C NSCLC Models Are Sensitive to Direct Targeting of KRAS in Combination with PI3K Inhibition

Clinical cancer research, 2019-01, Vol.25 (2), p.796-807

2019

Volltextzugriff (PDF)

The translational landscape of mTOR signalling steers cancer initiation and metastasis

Nature (London), 2012-05, Vol.485 (7396), p.55-61

2012

Volltextzugriff (PDF)

B-1 Cell Lymphoma in Mice Lacking the Steroid and Xenobiotic Receptor, SXR

Molecular endocrinology (Baltimore, Md.), 2011-06, Vol.25 (6), p.933-943

2011

Volltextzugriff (PDF)

An Internally Controlled Quantitative Target Occupancy Assay for Covalent Inhibitors

Scientific reports, 2018-09, Vol.8 (1), p.14312-7, Article 14312

2018

Volltextzugriff (PDF)

Next-generation flow cytometry

Nature biotechnology, 2011-07, Vol.29 (7), p.602-604

2011

Volltextzugriff (PDF)

Selective Inhibition of Phosphoinositide 3-Kinase p110α Preserves Lymphocyte Function

The Journal of biological chemistry, 2013-02, Vol.288 (8), p.5718-5731

2013

Volltextzugriff (PDF)

Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells

The Journal of clinical investigation, 2008-09, Vol.118 (9), p.3038-3050

2008

Volltextzugriff (PDF)

The reactivity-driven biochemical mechanism of covalent KRASG12C inhibitors

Nature structural & molecular biology, 2018-06, Vol.25 (6), p.454-462

2018

Volltextzugriff (PDF)

Immune regulation by rapamycin: moving beyond T cells

Science signaling, 2009-04, Vol.2 (67), p.pe25

2009

Volltextzugriff (PDF)

Targeting TOR dependence in cancer

Oncotarget, 2010-05, Vol.1 (1), p.69-76

2010

Volltextzugriff (PDF)

Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells

The Journal of clinical investigation, 2017-06, Vol.127 (6), p.2438-2438

2017

Volltextzugriff (PDF)

Sphingolipid-based drugs selectively kill cancer cells by down-regulating nutrient transporter proteins

Biochemical journal, 2011-10, Vol.439 (2), p.299-311

2011

Volltextzugriff (PDF)

The in vivo evaluation of active-site TOR inhibitors in models of BCR-ABL+ leukemia

Methods in molecular biology (Clifton, N.J.), 2012, Vol.821, p.251

2012

Volltextzugriff (PDF)

Crosstalk between the IGF1 and CXCL12 Pathways Defines Objective Responses to the Farnesyl Transferase Inhibitor Tipifarnib in AML and PTCL Patients

Blood, 2018-11, Vol.132 (Supplement 1), p.5349-5349

2018

Volltextzugriff (PDF)

Abstract CT191: Mechanism of action of the farnesyltransferase inhibitor, tipifarnib, and its clinical applications

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.CT191-CT191

2019

Volltextzugriff (PDF)

The CXCL12/CXCR4 Pathway As a Potential Target of Tipifarnib in Acute Myeloid Leukemia and Myelodysplastic Syndromes

Blood, 2017-12, Vol.130, p.3957-3957

2017

Volltextzugriff (PDF)

Efficacy of the investigational mTOR kinase inhibitor MLN0128/INK128 in models of B-cell acute lymphoblastic leukemia

Leukemia, 2013-03, Vol.27 (3), p.586-594

2013

Volltextzugriff (PDF)

Next-generation flow cytometry: mass cytometry dramatically enhances the dimensionality of fluorescence-based flow cytometry for phenotypic analysis of heterogeneous cell populations

Nature biotechnology, 2011-07, Vol.29 (7), p.602

2011

Volltextzugriff (PDF)

1 – 25 von 318

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(296)
Mit Volltextzugriff
(261)

Publikationsform

Sprache

Englisch
(318)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer

Tipifarnib as a Precision Therapy for HRAS -Mutant Head and Neck Squamous Cell Carcinomas

Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor

Targeting of the MNK–eIF4E axis in blast crisis chronic myeloid leukemia inhibits leukemia stem cell function

Resistance to mTOR kinase inhibitors in lymphoma cells lacking 4EBP1

Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor

Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State

KRAS G12C NSCLC Models Are Sensitive to Direct Targeting of KRAS in Combination with PI3K Inhibition

The translational landscape of mTOR signalling steers cancer initiation and metastasis

B-1 Cell Lymphoma in Mice Lacking the Steroid and Xenobiotic Receptor, SXR

An Internally Controlled Quantitative Target Occupancy Assay for Covalent Inhibitors

Next-generation flow cytometry

Selective Inhibition of Phosphoinositide 3-Kinase p110α Preserves Lymphocyte Function

Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells

The reactivity-driven biochemical mechanism of covalent KRASG12C inhibitors

Immune regulation by rapamycin: moving beyond T cells

Targeting TOR dependence in cancer

Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells

Sphingolipid-based drugs selectively kill cancer cells by down-regulating nutrient transporter proteins

The in vivo evaluation of active-site TOR inhibitors in models of BCR-ABL+ leukemia

Crosstalk between the IGF1 and CXCL12 Pathways Defines Objective Responses to the Farnesyl Transferase Inhibitor Tipifarnib in AML and PTCL Patients

Abstract CT191: Mechanism of action of the farnesyltransferase inhibitor, tipifarnib, and its clinical applications

The CXCL12/CXCR4 Pathway As a Potential Target of Tipifarnib in Acute Myeloid Leukemia and Myelodysplastic Syndromes

Efficacy of the investigational mTOR kinase inhibitor MLN0128/INK128 in models of B-cell acute lymphoblastic leukemia

Next-generation flow cytometry: mass cytometry dramatically enhances the dimensionality of fluorescence-based flow cytometry for phenotypic analysis of heterogeneous cell populations

Suchergebnisse filtern